User profiles for Christof von Kalle
Christof von KalleCharité Berlin Institute of Health, Chair for Clinical and Translational Sciences Verified email at charite.de Cited by 57872 |
[PDF][PDF] Severe COVID-19 is marked by a dysregulated myeloid cell compartment
Coronavirus disease 2019 (COVID-19) is a mild to moderate respiratory tract infection, however,
a subset of patients progress to severe disease and respiratory failure. The mechanism …
a subset of patients progress to severe disease and respiratory failure. The mechanism …
[PDF][PDF] Ultra-high-throughput clinical proteomics reveals classifiers of COVID-19 infection
…, M Pfeiffer, S Hippenstiel, A Hocke, C Von Kalle… - Cell systems, 2020 - cell.com
The COVID-19 pandemic is an unprecedented global challenge, and point-of-care
diagnostic classifiers are urgently required. Here, we present a platform for ultra-high-throughput …
diagnostic classifiers are urgently required. Here, we present a platform for ultra-high-throughput …
[HTML][HTML] Stem-cell gene therapy for the Wiskott–Aldrich syndrome
…, L Maródi, JS Orange, C Von Kalle… - … England Journal of …, 2010 - Mass Medical Soc
<p id="p001">The Wiskott–Aldrich syndrome (WAS) is an X-linked recessive primary
immunodeficiency disorder associated with thrombocytopenia, eczema, and autoimmunity. We …
immunodeficiency disorder associated with thrombocytopenia, eczema, and autoimmunity. We …
Gene therapy for Wiskott-Aldrich syndrome—long-term efficacy and genotoxicity
…, MH Albert, M Schmidt, C von Kalle… - Science translational …, 2014 - science.org
Wiskott-Aldrich syndrome (WAS) is characterized by microthrombocytopenia, immunodeficiency,
autoimmunity, and susceptibility to malignancies. In our hematopoietic stem cell gene …
autoimmunity, and susceptibility to malignancies. In our hematopoietic stem cell gene …
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
S Hacein-Bey-Abina, C Von Kalle… - New England journal …, 2003 - Mass Medical Soc
To the Editor: We recently reported (April 18 issue) 1 the sustained correction of X-linked
severe combined immunodeficiency disease by ex vivo, retrovirally mediated transfer of the γc …
severe combined immunodeficiency disease by ex vivo, retrovirally mediated transfer of the γc …
[HTML][HTML] COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis
…, J Eils, N Ishaque, UG Liebert, C von Kalle… - Nature …, 2020 - nature.com
To investigate the immune response and mechanisms associated with severe coronavirus
disease 2019 (COVID-19), we performed single-cell RNA sequencing on nasopharyngeal …
disease 2019 (COVID-19), we performed single-cell RNA sequencing on nasopharyngeal …
Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy
…, P Leboulch, B l'Homme, P Bougnères, C Von Kalle… - science, 2009 - science.org
X-linked adrenoleukodystrophy (ALD) is a severe brain demyelinating disease in boys that
is caused by a deficiency in ALD protein, an adenosine triphosphate–binding cassette …
is caused by a deficiency in ALD protein, an adenosine triphosphate–binding cassette …
[HTML][HTML] Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients
…, DK Webb, M Schmidt, C Von Kalle… - The Journal of …, 2008 - Am Soc Clin Investig
X-linked SCID (SCID-X1) is amenable to correction by gene therapy using conventional
gammaretroviral vectors. Here, we describe the occurrence of clonal T cell acute lymphoblastic …
gammaretroviral vectors. Here, we describe the occurrence of clonal T cell acute lymphoblastic …
Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1
Gene transfer into hematopoietic stem cells has been used successfully for correcting lymphoid
but not myeloid immunodeficiencies. Here we report on two adults who received gene …
but not myeloid immunodeficiencies. Here we report on two adults who received gene …
Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy
Introduction Metachromatic leukodystrophy (MLD) is a neurodegenerative lysosomal
storage disease caused by arylsulfatase A (ARSA) deficiency. The disease primarily affects …
storage disease caused by arylsulfatase A (ARSA) deficiency. The disease primarily affects …